Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2003 1
2011 1
2012 1
2019 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Results by year
Filters applied: . Clear all
Page 1
Development of a novel NURR1/NOT agonist from hit to lead and candidate for the potential treatment of Parkinson's disease.
Lesuisse D, Malanda A, Peyronel JF, Evanno Y, Lardenois P, De-Peretti D, Abécassis PY, Barnéoud P, Brunel P, Burgevin MC, Cegarra C, Auger F, Dommergue A, Lafon C, Even L, Tsi J, Luc TPH, Almario A, Olivier A, Castel MN, Taupin V, Rooney T, Vigé X. Lesuisse D, et al. Among authors: evanno y. Bioorg Med Chem Lett. 2019 Apr 1;29(7):929-932. doi: 10.1016/j.bmcl.2019.01.024. Epub 2019 Jan 30. Bioorg Med Chem Lett. 2019. PMID: 30773432
SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms.
Griebel G, Perrault G, Simiand J, Cohen C, Granger P, Depoortere H, Françon D, Avenet P, Schoemaker H, Evanno Y, Sevrin M, George P, Scatton B. Griebel G, et al. Among authors: evanno y. CNS Drug Rev. 2003 Spring;9(1):3-20. doi: 10.1111/j.1527-3458.2003.tb00241.x. CNS Drug Rev. 2003. PMID: 12595909 Free PMC article. Review.